Immediate Adverse Events Following COVID-19 Vaccination in Australian Pharmacies: A Retrospective Review

Background: Four COVID-19 vaccines are approved for use in Australia: Pfizer-BioNTech BNT162b2 (Comirnaty), AstraZeneca ChAdOx1 (Vaxzevria), Moderna mRNA-1273 (Spikevax), and Novavax NVX-CoV2373 (Nuvaxovid). We sought to examine the type and management of immediate adverse events following immunisat...

Descripción completa

Detalles Bibliográficos
Autores principales: Gallo, Alexander T., Scanlon, Lisa, Clifford, Jade, Patten-Williams, Lawson, Tweedie, Lachlan, Li, Dani, Salter, Sandra M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9787804/
https://www.ncbi.nlm.nih.gov/pubmed/36560451
http://dx.doi.org/10.3390/vaccines10122041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9787804/
https://www.ncbi.nlm.nih.gov/pubmed/36560451
http://dx.doi.org/10.3390/vaccines10122041

Ejemplares similares